{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:20:27Z","timestamp":1795101627821,"version":"4.10.3"},"reference-count":31,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite current therapies, there remains an unmet need for treatment for patients with hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for once-daily, subcutaneous concizumab prophylaxis in patients with hemophilia A\/B with inhibitors (HAwI\/HBwI; explorer4) and severe hemophilia A without inhibitors (HA; explorer5). Here, we present results from extension parts of these trials, included to evaluate longer term safety and efficacy. Both trials included main (\u226524 weeks) and extension (52-102 weeks) parts, with patients receiving concizumab 0.15 mg\/kg with potential dose escalation to concizumab 0.20 or 0.25 mg\/kg if they experienced \u22653 treated spontaneous bleeding episodes within 12 weeks. Endpoints included annualized bleeding rate (ABR), adverse events (AEs), and occurrence of antidrug antibodies. Thromboembolic events were AEs of special interest. Thirty-six patients with HA, 15 with HAwI, and 10 with HBwI were exposed to concizumab. Estimated ABRs during the main\u00a0+ extension parts at last dose level were 4.8 (95% confidence interval [CI], 3.2-7.2) and 6.4 (95% CI, 4.1-9.9) in explorer4 and explorer5, respectively (spontaneous ABRs were 1.8\u00a0[95% CI, 1.2-2.6] and 2.1 [95% CI, 1.3-3.3]). Most AEs were mild, with no deaths, events leading to withdrawal, or thromboembolic events. Anti-drug antibodies developed in 25% of patients and were low titer and transient, with no observed clinical effect in most cases. Results of the main + extension parts of these trials were consistent with results of the main parts. Ongoing phase 3 trials will further evaluate concizumab as a once-daily, subcutaneous treatment across hemophilia subtypes. These trials were registered at www.clinicaltrials.gov as #NCT03196284 and #NCT03196297.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006403","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T19:59:03Z","timestamp":1647374343000},"page":"3422-3432","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors"],"prefix":"10.1182","volume":"6","author":[{"given":"Amy D.","family":"Shapiro","sequence":"first","affiliation":[{"name":"1Indiana Hemophilia & Thrombosis Center, Indianapolis, IN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2483","authenticated-orcid":false,"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[{"name":"3Center for Thrombosis and Haemostasis, Lund University, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Benson","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Belfast Health and Social Care Trust, Belfast, Northern Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Eichler","sequence":"additional","affiliation":[{"name":"6Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg\/Saar, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-3499","authenticated-orcid":false,"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"7Haematology Department, La Paz University Hospital, Universidad Aut\u00f3noma Madrid, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Ege University Children\u2019s Hospital, Izmir, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"9Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[{"name":"10The Hemophilia Centre, Department of Haematology, Aarhus University, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-4873","authenticated-orcid":false,"given":"Allison P.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"11Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[{"name":"12Hemostasis and Thrombosis Center, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-2336","authenticated-orcid":false,"given":"Silva","family":"Zupan\u010di\u0107-\u0160alek","sequence":"additional","affiliation":[{"name":"13Department of Haematology, and Haemophilia and Thrombosis Unit, University Hospital Centre Zagreb, Zagreb, Croatia;"},{"name":"14School of Medicine, University of Osijek, Osijek, Croatia;"},{"name":"15School of Medicine, University of Zagreb, Zagreb, Croatia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"16Department of Immunohematology, and"},{"name":"17Department of Molecular Hemostasis, Institute of Experimental Hematology and Transfusion Medicine, University Clinic, Bonn, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"18Katharine Dormandy Hemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"3","key":"2022060815223398800_B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/rth2.12314","article-title":"Hemophilia management: huge impact of a tiny difference","volume":"4","author":"Kloosterman","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"key":"2022060815223398800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia."},{"key":"2022060815223398800_B3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence."},{"issue":"1","key":"2022060815223398800_B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/hae.13111","article-title":"European retrospective study of real-life haemophilia treatment","volume":"23","author":"Berntorp","year":"2017","journal-title":"Haemophilia."},{"issue":"3","key":"2022060815223398800_B5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022060815223398800_B6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia."},{"issue":"1","key":"2022060815223398800_B7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13023-018-0800-z","article-title":"European principles of inhibitor management in patients with haemophilia","volume":"13","author":"Giangrande","year":"2018","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"2022060815223398800_B8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica."},{"issue":"1","key":"2022060815223398800_B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia."},{"issue":"5","key":"2022060815223398800_B10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2516.2009.02039.x","article-title":"Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)","volume":"15","author":"Chitlur","year":"2009","journal-title":"Haemophilia."},{"issue":"23","key":"2022060815223398800_B11","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2022060815223398800_B12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther."},{"issue":"5","key":"2022060815223398800_B13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood."},{"key":"2022060815223398800_B14","author":"ClinicalTrials.gov"},{"issue":"24","key":"2022060815223398800_B15","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood."},{"issue":"11","key":"2022060815223398800_B16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost."},{"issue":"22","key":"2022060815223398800_B17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022060815223398800_B18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13627","article-title":"Concizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic\/pharmacodynamic modelling results of concizumab phase 1\/1b data","volume":"25","author":"Eichler","year":"2019","journal-title":"Haemophilia."},{"key":"2022060815223398800_B19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events","volume":"136","author":"Seremetis","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2022060815223398800_B20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia."},{"key":"2022060815223398800_B21","first-page":"PB 0503","article-title":"Safety and efficacy of concizumab prophylaxis following a switch from rFVIIa on-demand treatment: sub-analysis results from the phase 2 explorer4 trial in patients with hemophilia A or B with inhibitors","volume":"5(suppl 2),","author":"Shapiro","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"key":"2022060815223398800_B22","article-title":"Immunogenicity in the concizumab phase 2 clinical trials: clinical impact of anti-drug antibodies","volume":"5","author":"Hummelsh\u00f8j Landsy","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"key":"2022060815223398800_B23","first-page":"146","article-title":"BAY 1093884 binds to the Kunitz 1 and 2 domain interface of tissue factor pathway inhibitor and inhibits its function","volume":"1","author":"Yegneswaran","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"2022060815223398800_B24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"9","key":"2022060815223398800_B25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med."},{"key":"2022060815223398800_B26","author":"World Federation of Hemophilia"},{"key":"2022060815223398800_B27","author":"World Federation of Hemophilia"},{"issue":"6","key":"2022060815223398800_B28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/hae.12994","article-title":"TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia."},{"issue":"3","key":"2022060815223398800_B29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1189\/jlb.0212072","article-title":"Trauma equals danger\u2014damage control by the immune system","volume":"92","author":"Stoecklein","year":"2012","journal-title":"J Leukoc Biol."},{"key":"2022060815223398800_B30","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2019-122827","article-title":"Concizumab subcutaneous prophylaxis improves health-related quality-of-life measures in patients with congenital hemophilia with inhibitors: phase 2 trial results","volume":"134","author":"Lee","year":"2019","journal-title":"Blood."},{"key":"2022060815223398800_B31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/JBM.S50644","article-title":"Optimal management of hemophilic arthropathy and hematomas","volume":"5","author":"Lobet","year":"2014","journal-title":"J Blood Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3422\/1900431\/advancesadv2021006403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3422\/1900431\/advancesadv2021006403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:23:09Z","timestamp":1654701789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3422\/484399\/Long-term-efficacy-and-safety-of-subcutaneous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006403","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}